An interventional study of routine ICU nursing and HAI prevention in Patient Care Bundles, Interdisciplinary Communication and Intensive Care Units (ICUs), sponsored by The First Hospital of Qinhuangdao. Completed at 1 site in China. Open to participants aged 18 Years to 86 Years. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by The First Hospital of Qinhuangdao · Not applicable, Interventional, and Supportive care
Among 10 studies in Cross Infection with a site in China — 2 open to participants now, 3 under way, none of them phase 3. Cross Infection · China.
Among the 10 studies in Cross Infection with a site in China, this one is the only one that started in 2023, is one of 6 with no phase, and was the 10th registered.
285 studies on the registry are indexed under Cross Infection; 48 are open to participants now.
This study's enrollment of 120 is below the median of 185 across 169 interventional studies indexed under Cross Infection.
Browse Cross Infection studies →2 of the 10 studies in Cross Infection with a site in China are open now, in 2 countries. Each count lists the studies.
Of the 27 Cross Infection studies recruiting now, 22 (81%) set no upper age limit and 3 (11%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 86 Years · all sexes · no healthy volunteers.
The full table on the hub →10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2023.
Median enrollment 372 across the 7 interventional studies, 500 across the 3 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
1 of 10 have an industry lead sponsor. The 9 most frequent:
The First Hospital of Qinhuangdao is the lead sponsor of 22 studies on the registry; 1 is open to participants now.
The First Hospital of Qinhuangdao has 1 study filed under Cross Infection — fewer than ten, so there is no comparison to draw.
1 of the studies in Cross Infection with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07280026The Hong Kong Polytechnic UniversityEffectiveness of an Edge AI-based Augmented Reality System for Hand Hygiene Training: a Multi-centre, Mixed-methods Cluster Randomised Controlled Trial | 2027-08-01 |
Among the 10 studies in Cross Infection with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This study aims to evaluate the impact of a multidisciplinary collaborative bundle nursing intervention based on targeted surveillance on the incidence of ICU device-associated infections (DAIs). The control group received routine nursing care, while the intervention group implemented a "targeted surveillance-multidisciplinary collaboration-bundle intervention" system. Infection rates, clinical outcomes, and intervention implementation were compared between the two groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
routine ICU nursing and HAI prevention and control protocols
Behavioral: routine ICU nursing · Behavioral: HAI prevention · Behavioral: prevention and control collaboration
"Targeted Surveillance-Multidisciplinary Collaboration-Bundle Intervention" trinity system
Behavioral: real-time and precise monitoring · Behavioral: Multidisciplinary collaboration mechanism aimed for "efficiency and coordination." · Behavioral: CAUTI prevention and control · Behavioral: VAP prevention and control · Behavioral: CLABSI prevention and control
For device care: urinary catheter daily cleaning (wiping the urethral orifice and proximal 5cm of the catheter with a dedicated sterile wet wipe twice a day); ventilator circuit replacement once a week (prompt replacement if contaminated or damaged); CVC exit site care: dressing change within 24 hours after catheter placement, film dressing replacement every 7 days, and gauze dressing replacement every 2 days.
the infection control department summarized infection data monthly, including the number of infections and pathogen types, and provided a paper report to the ICU without real-time data feedback or early warning mechanisms.
the nursing department solely led HAI prevention and control. Temporary consultations with doctors and laboratory personnel were organized only in case of MDRO outbreaks or special infections, with no fixed collaboration process.
Daily records of urinary catheter, ventilator, and CVC dwell days; infection onset time ; pathogen type. APACHE II score (assessed at admission by doctors, calculated via HIS after morning rounds; responsible nurses assist at 8:00 daily); SOFA score (assessed at admission, calculated after morning rounds; nurses assist at 16:00 daily); consciousness status (GCS score).Compliance rate of bundle measures (qualified daily inspections/total cases); MDRO report response time (from lab report to isolation implementation). Real-time monitoring automatically captured data via HIS/LIS and the Lanqingting platform, with daily updates of device use and vital signs. Regular analysis: weekly multidisciplinary meetings (Wednesdays 15:00) to review infection data and implementation issues. Early warning: infection rate thresholds (CAUTI \>4.289‰, VAP \>7.775‰, CLABSI \>1.425‰); automatic alerts when thresholds exceeded or MDRO infections occurred.
A collaborative team: infection control (2 persons, data analysis \& supervision), medical affairs (1, coordination \& process optimization), nursing (2, training \& implementation inspection), ICU (3 doctors + 5 nurses, assessment \& measure execution), clinical lab (2, pathogen identification \& rapid reporting), and clinical pharmacy (1, antimicrobial guidance). Upon MDRO detection, the lab reported identification and susceptibility via WeChat within 10 min. Clinicians issued isolation orders within 30 min. Nurses implemented contact isolation within 1 hour. Infection control staff conducted on-site supervision within 24 hours, documenting and providing feedback. Regular communication: weekly multidisciplinary meetings to review progress, discuss difficulties, and adjust interventions.
Strict aseptic intubation (maximum sterile barrier, hand hygiene before intubation, disinfection of the urethral orifice with 0.05% povidone-iodine twice); daily assessment of extubation indicators (assessment by doctors during morning rounds combined with patient condition and urinary function, extubation within 24 hours if eligible); closed drainage system (avoiding repeated opening of the drainage bag, keeping the urine collection bag below bladder level, replacement once a week); perineal care (wiping with 0.05% povidone-iodine twice a day, in the order of urethral orifice-vaginal orifice-anus). All the following diagnostic criteria must be simultaneously satisfied.
Semi-recumbent position (head of bed elevated 30-45°, adjusted and angle recorded every 2 hours); daily awakening trial (discontinuing sedatives at 9:00 daily to assess patient consciousness and spontaneous breathing ability, initiating weaning process if eligible); oral care (gargling with 0.12% chlorhexidine solution every 8 hours, wiping teeth, gums, and tongue surface; for non-intubated patients: gargling with 0.12% chlorhexidine solution twice a day, wiping teeth, gums, and tongue surface); continuous instillation of sterile water for injection (3 bottles per day, maintaining continuous moistening of the oral mucosa); replacement of ventilator circuit humidification fluid (using sterile distilled water, replacement once a day, maintaining water level within the standard range).
Aseptic intubation (selecting an appropriate puncture site, preferring ultrasound-guided puncture, maximum sterile barrier, skin disinfection with 2% chlorhexidine alcohol wiping ≥15cm in diameter, waiting for drying before intubation); daily assessment of extubation indicators (timely extubation if no clear indication based on treatment needs and patient condition); CVC exit site care (disinfection with 2% chlorhexidine alcohol, replacement of sterile dressings twice a week, prompt replacement if oozing or contamination occurs); avoiding unnecessary catheter maintenance (replacing dressings only when loose, contaminated, or in case of puncture site infection, avoiding routine catheter replacement).
incidence of DAIs
calculation method: the ratio of the number of DAI cases to the total number of device indwelling days of all patients in the group, multiplied by 1000‰
Time frame: from enrollment to transfer from the ICU or discharge, an average of 17 days
duration of antimicrobial use
total days from antimicrobial initiation to discontinuation
Time frame: start from using antibiotics until discontinuation or discharge, an average of about 30 days
length of ICU stay
days from ICU admission to transfer or discharge
Time frame: from ICU admission to ICU transfer or discharge, an average of about 17 days
total length of hospital stay
days from admission to discharge
Time frame: from admission to discharge, an average of about 53 days
mortality
death at discharge
Time frame: assessment at discharge, an average of 53 days after admission
Ran from Jan 2023 to primary completion in Dec 2025, 35 months.
Of 57 non-industry interventional studies with no phase under Cross Infection, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 35 months is above that.
Counting every sponsor, half of 59 studies reached it within 16 months; a quarter within 6 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Hospital of Qinhuangdao